Is there a link between androgenetic alopecia and COVID-19?
KeywordsCOVID-19, SARS-CoV-2, androgenic alopecia, antiandrogen drugs
Introduction and purpose: 20% of COVID-19 cases require hospitalization, with men most often being affected. Current studies indicate a relationship between the incidence and severity of the disease and androgens, including a worse prognosis in patients with androgenetic alopecia. The aim of the study is to analyze the available literature in the Pubmed and Google scholar database in order to find an answer to the question of whether there is a cause-and-effect relationship between androgenetic alopecia and COVID-19.
State of knowledge: Male sex hormones, androgen receptors, the presence of substances inducing the development of the inflammatory process and genetic factors are important in the pathogenesis of androgenetic alopecia. It has been noted that androgens are involved in the entry of SARS-CoV-2 into cells and the reduction of the inflammatory response of the body that contribute to the development of the disease. On the one hand, patients hospitalized due to SARS-CoV-2 infection have low levels of male sex hormones, and on the other hand, diseases associated with increased levels of androgens, such as androgenetic alopecia or prostate cancer, are associated with more frequent incidence.
Summary: The relationship of androgens to the development of COVID-19 is not clear. Therefore, the relationship of this disease with androgenetic alopecia cannot be directly explained and there is a need for further research.
Batrinos ML. The endocrinology of baldness. Hormones. 2014; 13(2): 197-212.
Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel coronavirus infection (COVID‐19) in humans: a scoping review and meta‐analysis. J Clin Med. 2020;9(4):941.
Brzezińska-Wcisło, Ligia, et al. Androgenetic alopecia. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegląd dermatologiczny/ Dermatology Review. 2018; 105.1: 1-18.
Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J. Immunol. 2017;198:4046–4053.
Darwin E, Hirt PA, Fertig R et al. Alopecia areata: Review of epidemiology, clinical features, pathogenesis, and new treatment options. International journal of trichology. 2018; 10(2): 51.
Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. Journal of cosmetic dermatology. 2019; 18(4): 966-975.
Ho CH, Zito PM. Androgenetic Alopecia. 2019.
McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett. 2012; 17(6): 1-4.
Mohamed S. Mohamed, Thiago C. Moulin, Helgi B. Schiöth. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2021; 71.1: 3-8.
Moravvej, Hamideh, et al. Androgenetic alopecia and COVID‐19: A review of the hypothetical role of androgens. Dermatologic therapy. 2021; e15004.
Pozzilli P, Lenzi A. Commentary: testosterone, a key hormone in the context of COVID‐19 pandemic. Metabolism. 2020;108:154252.
Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2020;00:1–11.
Rzepa T, Kubaszewski P, Żaba R. Wybrane charakterystyki psychospołeczne pacjentów z łysieniem androgenowym–badanie wstępne. Hygeia. 2017. 52(1): 60-63.
M. Schroeder, B. Tuku, D. Jarczak, A. Nierhaus, T. Bai, H. Jacobsen et al. The majority of male patients with COVID-19 present low testosterone levels on admission to Intensive Care in Hamburg, Germany: a retrospective cohort study. medRxiv. 2020.
C.G. Wambier, A. Goren, S. Vaño-Galván, P.M. Ramos, A. Ossimetha, G. Nau et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. Wiley-Liss Inc. 2020.
How to Cite
Copyright (c) 2021 © The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 317
Number of citations: 0